Credit, Dr Michael May/Dr Wungki Park/Memorial Sloan Kettering Cancer Center/Press Association
Experts say they are facing the biggest advance in the treatment of pancreatic cancer in decades: a daily pill that appears to shrink and possibly even eliminate tumors in some patients with one of the most lethal and difficult to treat types of the disease.
This is the drug daraxonrasib. In the first clinical trials, imaging studies of one of the 12 patients who received the drug together with chemotherapy showed the disappearance of detectable tumors.
And almost all of the 61 trial participants who had recently been diagnosed with advanced pancreatic cancer that had spread to other parts of the body saw their tumors stop growing.
However, doctors emphasize that it is not clear how long the medicine is able to keep the disease under control. The pill shouldn't be seen as a cure either, they say.
Incredibly exciting
Cancer Research UK, the world's largest independent cancer research organization based in the United Kingdom, called the discovery "the biggest breakthrough in decades" for pancreatic cancer patients.
Sam Godfrey, who is part of the charity, told BBC News that the results were incredibly encouraging: "What this new medicine has done is found a way to medicate what was previously considered untreatable."
"We are finally seeing progress in the treatment of pancreatic cancer, something that should have happened a long time ago," he said.
Pancreatic cancer is notoriously difficult to treat. In the UK, it has the lowest survival rate of all common cancers.
End of Most read
Pancreatic cancer is also among those with the lowest 5-year survival rate and highest lethality rate in Brazil, according to a global cancer survival surveillance study.
Although chemotherapy can shrink tumors somewhat, this cancer often grows back over time.
Most patients with advanced disease survive months, not years.
Doctors hope the new treatment can give patients more time, even if it can't stop cancer permanently.
The study followed patients for an average of a year and a half, and some did not see their cancer return during that time.
Longer studies are needed to understand whether any of these cancers can go into remission and for how long.
In phase 1/2 clinical trial:
Longer survival
Watch news from Brazil and the world on the BBC World Service
Download here
End of app promotion
Wungki Park, from Memorial Sloan Kettering Cancer Center in the USA, who is involved in the study, said the results are extremely encouraging so far.
"We are starting to see not only a higher percentage of tumor response rates, but also deeper responses and a near doubling in the duration of disease control, which could eventually translate into improved survival," he said.
Daraxonrasib is a targeted inhibitor treatment that has already been approved in the US. It works by binding and deactivating certain mutations, called RAS, found in most pancreatic cancers and which drive tumor growth.
Dozens of other types of cancer, including lung and ovarian cancer, can have similar mutations, meaning the drug could help many other patients as well.
"I hope that the initial success we are starting to see in pancreatic cancer can be replicated in other types of cancer," said Godfrey of Cancer Research UK.
The doctor says longer tests and more accurate results are vital. "Cancer can come back, and even if scans don't show any signs of it, you don't necessarily know if you're cancer-free until more time has passed," he says.
Professor Elena Garralda, chair of the European cancer conference EORTC–NCI–AACR Symposium 2026, where the work is being presented to other clinicians, said: "These results are encouraging because they show that combination treatment can potentially significantly improve patients' overall survival, as well as the time until tumors start to grow again."
In Brazil, 14,379 deaths from pancreatic cancer were recorded in 2024 (6.8 deaths per 100 thousand inhabitants).
In the United Kingdom, 11,500 cases of the disease are diagnosed per year and around 10,200 deaths occur, according to Cancer Research UK.
Actor Alan Rickman, best known for playing Severus Snape in the Harry Potter saga, died from the disease in 2016, five months after his diagnosis.
Symptoms may include jaundice, itchy skin, darker urine, lighter stools, unexplained weight loss, tiredness and high fever.
Discover more
Watch
End of Watch




